
US Patent No: 4,259,314
Number of patents in Portfolio can not be more than 2000
Method and composition for the preparation of controlled long-acting pharmaceuticals
Stats
-
Mar 31, 1981
Issued date -
Dec 10, 1979
filing date -
06/102,227
serial no -
Expired
status

Importance
Loading Importance Indicators...
Overall
|
US Family Size
|
International Coverage
|
Patent Longevity
|
Forward Citations
|
Abstract
A method and composition for the preparation of controlled long-acting pharmaceuticals using a dry carrier or base material comprising an effective amount of hydroxypropyl methylcellulose and hydroxypropyl cellulose suitable for use with both hygroscopic and non-hygroscopic materials. The controlled long-acting products of the invention are suitable for use in the form of lozenges, buccal tablets, oral tablets or suppositories.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
- Assignment data not available. Check USPTO
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Inventor(s)
| Inventor Name | Address | # of filed Patents | Total Citations |
|---|---|---|---|
| Lowey, Hans | 1045 Nine Acres La., Mamaroneck, NY 10541 | 4 | 183 |
Cited Art
- No Cited Art to Display
Patent Citation Ranking
Forward Cites
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 4,366,310 Controlled release compositions | 27 | 1980 | |
| 5,891,471 Pharmaceutical multiparticulates | 50 | 1996 | |
| 5,849,240 Method of preparing sustained release pharmaceutical compositions | 59 | 1996 | |
| 5,843,480 Controlled release diamorphine formulation | 41 | 1996 | |
| 6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same | 38 | 1997 | |
| 5,965,163 Substained release compositions and a method of preparing pharmaceutical compositions | 58 | 1997 | |
| 6,162,467 Sustained release compositions and a method of preparing pharmaceutical compositions | 41 | 1999 | |
|
|
|||
| 4,994,276 Directly compressible sustained release excipient | 69 | 1988 | |
| 5,128,143 Sustained release excipient and tablet formulation | 63 | 1990 | |
| 5,135,757 Compressible sustained release solid dosage forms | 43 | 1991 | |
| 5,169,639 Controlled release verapamil tablets | 33 | 1991 | |
| 5,472,711 Agglomerated hydrophilic complexes with multi-phasic release characteristics | 31 | 1992 | |
| 5,478,574 Agglomerated hydrophilic complexes with multi-phasic release characteristics | 27 | 1993 | |
| 5,670,168 Agglomerated hydrophilic complexes with multi-phasic release characteristics | 22 | 1996 | |
|
|
|||
| 5,965,161 Extruded multi-particulates | 60 | 1994 | |
| 5,958,452 Extruded orally administrable opioid formulations | 76 | 1997 | |
| 6,335,033 Melt-extrusion multiparticulates | 40 | 1999 | |
| 6,261,599 Melt-extruded orally administrable opioid formulations | 63 | 1999 | |
| 6,743,442 Melt-extruded orally administrable opioid formulations | 16 | 2001 | |
| 6,706,281 Melt-extrusion multiparticulates | 15 | 2002 | |
| 7,510,727 Melt-extrusion multiparticulates | 0 | 2003 | |
|
|
|||
| 4,369,172 Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | 210 | 1981 | |
| 4,389,393 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose | 206 | 1982 | |
| 4,795,327 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants | 31 | 1984 | |
| 4,540,566 Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose | 64 | 1984 | |
| 4,849,229 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants | 27 | 1988 | |
| 4,983,398 Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates | 23 | 1988 | |
|
|
|||
| 6,372,252 Guaifenesin sustained release formulation and tablets | 9 | 2000 | |
| 6,955,821 Sustained release formulations of guaifenesin and additional drug ingredients | 4 | 2002 | |
| 7,985,420 Sustained release of guaifenesin combination drugs | 0 | 2003 | |
| 7,838,032 Sustained release of guaifenesin | 0 | 2003 | |
| 8,012,504 Sustained release of guaifenesin combination drugs | 1 | 2003 | |
| 7,985,421 Sustained release formulations of guaifenesin and additional drug ingredients | 0 | 2005 | |
|
|
|||
| 4,786,503 Dosage form comprising parallel lamine | 30 | 1987 | |
| 4,851,232 Drug delivery system with means for obtaining desirable in vivo release rate pattern | 36 | 1987 | |
| 4,946,685 Cellulosic dosage form | 56 | 1988 | |
| 5,204,116 Dosage form providing immediate therapy followed by prolonged therapy | 18 | 1991 | |
| 5,338,550 Stereoisomer therapy | 7 | 1992 | |
|
|
|||
| 4,505,890 Controlled release formulation and method | 22 | 1983 | |
| 4,610,870 Controlled release formulation | 71 | 1984 | |
| 4,666,705 Controlled release formulation | 40 | 1985 | |
| 4,756,911 Controlled release formulation | 74 | 1986 | |
|
|
|||
| 5,591,452 Controlled release formulation | 50 | 1994 | |
| 6,326,027 Controlled release formulation | 37 | 1995 | |
| 6,254,887 Controlled release tramadol | 35 | 1996 | |
| 7,074,430 Controlled release tramadol tramadol formulation | 9 | 2001 | |
|
|
|||
| 5,484,607 Extended release clonidine formulation | 7 | 1993 | |
| 5,869,100 Extended release clonidine formulation (tablet) | 3 | 1997 | |
| 6,030,642 Extended release clonidine formulation (capsule) | 3 | 1997 | |
| 7,884,122 Extended release formulation and method of treating adrenergic dysregulation | 0 | 2009 | |
|
|
|||
| 7,781,448 Once daily dosage forms of trospium | 0 | 2007 | |
| 7,781,449 Trospium chloride treatment method | 0 | 2007 | |
| 7,763,635 Once daily dosage forms of trospium | 2 | 2007 | |
| 7,759,359 Method of treating bladder dysfunction with once-a-day trospium salt formulation | 0 | 2007 | |
|
|
|||
| 6,818,229 Intermediate release nicotinic acid compositions for treating hyperlipidemia | 4 | 1997 | |
| 6,746,691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics | 4 | 1997 | |
| 6,676,967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia | 4 | 1997 | |
|
|
|||
| 4,508,702 Sustained release aspirin | 11 | 1984 | |
| 4,555,399 Aspirin tablet | 38 | 1984 | |
| 4,634,587 Sustained release quinidine dosage form | 18 | 1984 | |
|
|
|||
| 6,242,003 Organic compounds | 4 | 2000 | |
| 6,432,447 Organic compounds | 1 | 2001 | |
| 8,303,987 Pharmaceutical compositions comprising fluvastatin | 0 | 2010 | |
|
|
|||
| 4,601,894 Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate | 20 | 1985 | |
| 4,695,591 Controlled release dosage forms comprising hydroxypropylmethylcellulose | 40 | 1985 | |
| 4,657,757 Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate | 14 | 1985 | |
|
|
|||
| 4,695,464 Sustained release dosage form based on highly plasticized cellulose ether gels | 26 | 1984 | |
| 4,678,516 Sustained release dosage form based on highly plasticized cellulose ether gels | 56 | 1984 | |
| 4,734,285 Sustained release compositions | 36 | 1985 | |
|
|
|||
| 5,645,830 Lactobacillus and skim milk compositions and methods for preventing microbial urogenital infections | 11 | 1994 | |
| 6,004,551 Lactobacillus and skim milk pharmaceutical compositions | 8 | 1996 | |
|
|
|||
| 5,480,984 Process of preparing high solids low viscosity polysaccharides | 6 | 1992 | |
| 6,210,710 Sustained release polymer blend for pharmaceutical applications | 26 | 1997 | |
|
|
|||
| 6,080,428 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor | 3 | 1995 | |
| 6,129,930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night | 6 | 1997 | |
|
|
|||
| 4,465,660 Sustained release tablet containing at least 95 percent theophylline | 22 | 1982 | |
| 4,547,358 Sustained release tablet containing at least 95 percent theophylline | 9 | 1984 | |
|
|
|||
| 5,126,145 Controlled release tablet containing water soluble medicament | 96 | 1990 | |
| 5,268,181 Method of using niacin to control nocturnal cholesterol synthesis | 17 | 1992 | |
|
|
|||
| 6,821,532 Methods and compositions for the treatment of benign prostatic hypertrophy | 2 | 2001 | |
| 6,733,796 Methods and compositions for the treatment of benign prostatic hypertrophy | 3 | 2002 | |
|
|
|||
| 4,942,040 Pharmaceutical preparation and a process for its preparation | 37 | 1988 | |
|
|
|||
| 4,916,138 Solid dispersion composition of FR-900506 substance | 45 | 1988 | |
|
|
|||
| 5,445,829 Extended release pharmaceutical formulations | 126 | 1992 | |
|
|
|||
| 6,214,381 Methazolamide composition and method of use | 0 | 1998 | |
|
|
|||
| 6,110,494 Cisapride mini-tablet formulations | 3 | 1997 | |
|
|
|||
| 4,837,032 Theophylline sustained release tablet | 18 | 1986 | |
|
|
|||
| 4,654,206 Fast release solid preparation of dihydropyridine a compound | 13 | 1984 | |
|
|
|||
| 5,393,765 Pharmaceutical compositions with constant erosion volume for zero order controlled release | 29 | 1993 | |
|
|
|||
| 7,998,506 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor | 0 | 2003 | |
|
|
|||
| 6,042,847 Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application | 21 | 1997 | |
|
|
|||
| 7,179,486 Process for preparing sustained release tablets | 3 | 2001 | |
|
|
|||
| 7,381,731 Pharmaceutical composition comprising citrulline | 0 | 2004 | |
|
|
|||
| 5,895,663 Pseudoephedrine hydrochloride extended-release tablets | 12 | 1997 | |
|
|
|||
| 6,960,356 Orally administered drug delivery system providing temporal and spatial control | 5 | 1999 | |
|
|
|||
| 5,948,440 Modified release matrix formulation of cefaclor and cephalexin | 8 | 1997 | |
|
|
|||
| 5,069,911 Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions | 3 | 1990 | |
|
|
|||
| 5,476,668 Base for film-coating pharmaceuticals and method for preparing same | 4 | 1993 | |
|
|
|||
| 5,061,493 Galenical forms of corticoids for administration perlingually and sublingually and process for their preparation | 1 | 1988 | |
|
|
|||
| 5,948,437 Pharmaceutical compositions using thiazepine | 13 | 1997 | |
|
|
|||
| 6,337,091 Matrix for controlled delivery of highly soluble pharmaceutical agents | 12 | 1997 | |
|
|
|||
| 6,893,661 Controlled release formulations using intelligent polymers | 3 | 1998 | |
|
|
|||
| 5,840,756 Pharmaceutical composition of L-DOPA ester | 23 | 1996 | |
|
|
|||
| 4,680,323 Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration | 33 | 1983 | |
| 4,775,535 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics | 22 | 1986 | |
| 4,855,143 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics | 21 | 1988 | |
| 6,264,974 Buccal and sublingual administration of physostigmine | 2 | 1998 | |
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |